Cover Image
市場調查報告書

PharmaPoint:多發性骨髓瘤 - 全球醫藥品市場預測與市場分析

PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 351341
出版日期 內容資訊 英文 262 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:多發性骨髓瘤 - 全球醫藥品市場預測與市場分析 PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023
出版日期: 2015年11月01日 內容資訊: 英文 262 Pages
簡介

本報告提供多發性骨髓瘤治療藥市場相關調查分析,疾病的概要與指南,競爭情形,主要藥物的詳細資訊 (產品說明,安全性,有效性) 、SWOT分析,銷售額預測,影響分析 (趨勢,推動因素、阻礙因素) 等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因、病理生理學
  • 分期
  • 應答與復發標準
  • 症狀
  • 預後
  • QOL

第4章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 全球趨勢
    • 發病率
    • 存活率
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法:確診的發病數量
    • 預測的前提條件與手法:5年確診的患者數
    • 預測的前提條件與手法:診斷時的各病期
  • 流行病學預測
    • 確診的發病數量
    • 確診的發病數量:各年齡
    • 確診的發病數量:性別
    • 確診的發病數量:年齡調整
    • 確診的患病人數:診斷時的各病期
    • 5年確診的患者數
  • 議論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第5章 疾病的管理

  • 治療概要
  • 診斷
  • 臨床診療
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 中國

第6章 競爭評估

  • 概要
  • 產品簡介

第7章 未滿足需求和機會

  • 概要
  • 高風險患者的治療
  • 和緩性骨髓瘤患者的治療
  • 髓外疾病的治療

第8章 開發平台評估

  • 概要
  • 臨床開發中的潛力藥物
  • 初期正在開發的有潛力的藥劑

第9章 現在、未來的主要企業

  • 企業策略趨勢
  • 企業簡介
    • Millennium Pharmaceuticals/武田藥品工業
    • Celgene
    • Onyx Pharmaceuticals/Amgen
    • Novartis
    • AbbVie
    • Bristol-Myers Squibb
    • Janssen

第10章 市場預測

  • 全球市場
  • 美國
  • EU5個國家
  • 日本
  • 中國

第11章 附錄

圖表

目錄
Product Code: GDHC114PIDR

The Multiple Myeloma (MM) market is currently dominated by Velcade and Revlimid, and the market is set to undergo substantial growth between 2013 and 2023. The main drivers of growth will be the launch of monoclonal antibodies (mAbs) Empliciti and daratumumab, which will not only provide a new treatment option for MM patients, but will also lengthen the time between relapses, meaning that the duration of Revlimid and/or Velcade treatments will also be longer. Furthermore, the relatively mild safety profile of these mAbs and the significant efficacies demonstrated by these agents will mean that more MM patients will ultimately receive drug treatment. Label extensions of these mAbs, as well as of second-generation proteasome inhibitors ixazomib and Kyprolis, will further increase treatment options for these patients. The biggest constrainers of the MM market are the increasing cost-consciousness of healthcare providers, as the launch and subsequent label extensions of these pipeline agents will lead to a significant expense, which may impact uptake of these drugs. The patent expiries of Revlimid and Velcade will somewhat alleviate healthcare spending on multiple myeloma patients, which may assist in the uptake of mAbs and second-generation PIs in the multiple myeloma market.

Highlights

Key Questions Answered

  • The multiple myeloma market is marked by the presence of a number of unmet needs. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of multiple myeloma market?
  • The late-stage multiple myeloma pipeline has therapies targeting different multiple myeloma populations. Which late-stage drugs will have the biggest impact in each patient population? Which of these drugs will have the highest peak sales at the highest CAGR, and why?
  • The current multiple myeloma market is dominated by Velcade and Revlimid. How will the advent of new mAbs change the drug treatment landscape for multiple myeloma? How will the drug treatment rate change over the next five years? What are the key drivers and barriers to this change?

Key Benefits

  • The main driver of the enormous expansion of the multiple myeloma market will be the launch of mAbs Empliciti and daratumumab.
  • The second largest driver will be the label extension of currently marketed drugs Kyprolis and Revlimid.
  • Another driver of the multiple myeloma market will be the ageing population in the 8MM, which will increase the number of multiple myeloma cases.
  • The increase in therapeutic options overall will lead to increases in treatment rates in the 8MM. Also, as triplet/quadruplet therapies increasingly become the standard of care within the forecast period, this will increase the duration of treatment for each patient as well as the number of treatments each patient receives.

Scope

  • Overview of multiple myeloma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized multiple myeloma therapeutics market revenue, average cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the multiple myeloma therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global multiple myeloma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global multiple myeloma therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global multiple myeloma therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global multiple myeloma therapeutics market from 2013-2023.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Staging Systems
  • 3.3. Response and Relapse Criteria
  • 3.4. Symptoms
  • 3.5. Prognosis
  • 3.6. Quality of Life

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
    • 4.3.1. Incidence
    • 4.3.2. Survival Rates for Multiple Myeloma - 8MM
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods, Multiple Myeloma Diagnosed Incident Cases
    • 4.4.4. Forecast Assumptions and Methods, Multiple Myeloma Five-Year Diagnosed Prevalent Cases
    • 4.4.5. Forecast Assumptions and Methods, Multiple Myeloma Clinical Stages at Diagnosis
  • 4.5. Epidemiological Forecast for Multiple Myeloma (2013-2023)
    • 4.5.1. Diagnosed Incident Cases of Multiple Myeloma
    • 4.5.2. Age-Specific Diagnosed Incident Cases of Multiple Myeloma
    • 4.5.3. Sex-Specific Diagnosed Incident Cases of Multiple Myeloma
    • 4.5.4. Age-Standardized Diagnosed Incidence of Multiple Myeloma
    • 4.5.5. Diagnosed Incident Cases of Multiple Myeloma by Clinical Stage at Diagnosis
    • 4.5.6. Five-Year Diagnosed Prevalent Cases of Multiple Myeloma
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Treatment Overview
  • 5.2. Diagnosis
  • 5.3. Clinical Practice
    • 5.3.1. Primary Therapy for SCT-Eligible Patients
    • 5.3.2. Primary Therapy for Non-SCT Patients
    • 5.3.3. Salvage/Relapse Therapy
    • 5.3.4. Leading Prescribed Drugs
  • 5.4. US
    • 5.4.1. Diagnosis
    • 5.4.2. Clinical Practice
  • 5.5. France
    • 5.5.1. Diagnosis
    • 5.5.2. Clinical Practice
  • 5.6. Germany
    • 5.6.1. Diagnosis
    • 5.6.2. Clinical Practice
  • 5.7. Italy
    • 5.7.1. Diagnosis
    • 5.7.2. Clinical Practice
  • 5.8. Spain
    • 5.8.1. Diagnosis
    • 5.8.2. Clinical Practice
  • 5.9. UK
    • 5.9.1. Diagnosis
    • 5.9.2. Clinical Practice
  • 5.10. Japan
    • 5.10.1. Diagnosis
    • 5.10.2. Clinical Practice
  • 5.11. China (Urban)
    • 5.11.1. Diagnosis
    • 5.11.2. Clinical Practice

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Product Profiles - Proteasome Inhibitors
    • 6.2.1. Velcade (Bortezomib)
    • 6.2.2. Kyprolis (Carfilzomib)
  • 6.3. Product Profiles - Immunomodulators
    • 6.3.1. Revlimid (Lenalidomide)
    • 6.3.2. Pomalyst/Imnovid (Pomalidomide)
  • 6.4. Other Therapeutic Classes

7. Unmet Need and Opportunity

  • 7.1. Overview
  • 7.2. Treatment of High-Risk Patients
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Treatment of Patients with Smoldering Myeloma
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Treatment of Extramedullary Disease
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Promising Drugs in Clinical Development
    • 8.2.1. Farydak (Panobinostat)
    • 8.2.2. Ixazomib
    • 8.2.3. Empliciti (Elotuzumab)
    • 8.2.4. Daratumumab
    • 8.2.5. Aplidin (Plitidepsin)
  • 8.3. Promising Drugs in Early-Stage Development
    • 8.3.1. Oprozomib (ONX-0912)
    • 8.3.2. Filanesib
    • 8.3.3. SAR650984
    • 8.3.4. Marizomib
    • 8.3.5. Evofosfamide
    • 8.3.6. LGH447
    • 8.3.7. Selinexor (KPT-330)

9. Current and Future Players

  • 9.1. Overview and Trends in Corporate Strategy
  • 9.2. Company Profiles
    • 9.2.1. Millennium Pharmaceuticals/Takeda
    • 9.2.2. Celgene
    • 9.2.3. Onyx Pharmaceuticals/Amgen
    • 9.2.4. Novartis
    • 9.2.5. AbbVie
    • 9.2.6. Bristol-Myers Squibb
    • 9.2.7. Janssen

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers - Global Issues
    • 10.1.3. Barriers - Global Issues
  • 10.2. US
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers - US
    • 10.2.4. Barriers - US
  • 10.3. 5EU
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers - 5EU
    • 10.3.4. Barriers - 5EU
  • 10.4. Japan
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers - Japan
    • 10.4.4. Barriers - Japan
  • 10.5. China (Urban)
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers - China (Urban)
    • 10.5.4. Barriers - China (Urban)

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed Multiple Myeloma Patients
    • 11.4.2. Percent of Drug-Treated Patients
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Individual Drug Assumptions
    • 11.4.7. Pricing of Pipeline Agents
    • 11.4.8. Generic Erosion
  • 11.5. Primary Research - KOLs Interviewed for this Report
  • 11.6. Primary Research - High-Prescriber Survey
  • 11.7. About the Authors
    • 11.7.1. Analyst
    • 11.7.2. Therapy Director
    • 11.7.3. Epidemiologist
    • 11.7.4. Global Head of Healthcare
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: Definition of the Classes of Myeloma
  • Table 2: Staging Systems for Multiple Myeloma
  • Table 3: IMWG Uniform Response Criteria for Multiple Myeloma: Response
  • Table 4: IMWG Uniform Response Criteria for Multiple Myeloma: Progression
  • Table 5: Symptoms of Multiple Myeloma
  • Table 6: Median Survival for Each Stage at Diagnosis of Multiple Myeloma
  • Table 7: Potential Diagnostic Markers that Predict Two-Year Disease Progression
  • Table 8: Summary of Prevalence and Clinical Outcomes of Translocations in Multiple Myeloma
  • Table 9: Multiple Myeloma Clinical Stages at Diagnosis, Using the ISS Criteria
  • Table 10: Risk Factors and Comorbidities for Multiple Myeloma
  • Table 11: Trends in the Age-Adjusted Incidence of Multiple Myeloma in the US, Ages ≥40 Years, 1993-2007
  • Table 12: Trends in the Age-Adjusted Incidence of Multiple Myeloma in the 5EU, Ages ≥40 Years, 1993-2007
  • Table 13: Trends in the Age-Adjusted Incidence of Multiple Myeloma in Japan, Ages ≥40 Years, 1993-2007
  • Table 14: Trends in the Age-Adjusted Incidence of Multiple Myeloma in Urban China, Ages ≥40 Years, 1993-2007
  • Table 15: Trends in the Five-Year Relative Survival (%) of Multiple Myeloma in the 8MM, Both Sexes, 1993-2009
  • Table 16: 8MM, Sources of Epidemiological Data Used for the Forecast for Multiple Myeloma Diagnosed Incident Cases
  • Table 17: 8MM, Sources of Epidemiological Data Used for the Forecast for Multiple Myeloma Diagnosed Five-Year Prevalent Cases
  • Table 18: 8MM, Sources of Epidemiological Data Used for the Segmentation of Multiple Myeloma Incident Cases by Clinical Stage at Diagnosis
  • Table 19: 8MM, Diagnosed Incident Cases of Multiple Myeloma, Both Sexes, Ages ≥40 Years, N, 2013-2023
  • Table 20: 8MM, Age-Specific Diagnosed Incident Cases of Multiple Myeloma, Both Sexes, N (Row %), 2013
  • Table 21: 8MM, Sex-Specific Diagnosed Incident Cases of Multiple Myeloma, Ages ≥40 Years, N (Row %), 2013
  • Table 22: 8MM, Five-Year Diagnosed Prevalent Cases of Multiple Myeloma, Both Sexes, Ages ≥40 Years, N, 2013-2023
  • Table 23: Treatment Guidelines for Multiple Myeloma
  • Table 24: Definition of the Classes of Myeloma
  • Table 25: Most Prescribed Drugs for Multiple Myeloma by Class in the Global Markets, 2014
  • Table 26: Most-Prescribed Drugs for Multiple Myeloma by Segment in the Global Markets, 2013
  • Table 27: Country Profile - US
  • Table 28: Country Profile - France
  • Table 29: Country Profile - Germany
  • Table 30: Country Profile - Italy
  • Table 31: Country Profile - Spain
  • Table 32: Country Profile - UK
  • Table 33: Country Profile - Japan
  • Table 34: Country Profile - China (Urban)
  • Table 35: Product Profile - Velcade
  • Table 36: Results from the Pivotal Phase III APEX Trial for Velcade
  • Table 37: Results from the Pivotal Phase III VISTA Trial for Velcade
  • Table 38 Results from the Subcutaneous versus Intravenous Velcade Phase III trial
  • Table 39: Common Grade 3 and 4 Adverse Events from Velcade Pivotal Clinical Trials
  • Table 40: Velcade SWOT Analysis, 2015
  • Table 41: Global Sales Forecast ($m) for Velcade, 2013-2023
  • Table 42: Product Profile - Kyprolis
  • Table 43 Summary of Phase III Pivotal Trial Results for Kyprolis
  • Table 44: Summary of Phase II Clinical Trial Efficacy Data for Kyprolis
  • Table 45 Summary of Adverse Events from Key Phase III Pivotal Trials for Kyprolis
  • Table 46: Kyprolis SWOT Analysis, 2015
  • Table 47: Global Sales Forecasts ($m) for Kyprolis, 2013-2023
  • Table 48: Product Profile - Revlimid
  • Table 49 Summary of Phase III Pivotal Trial Results for Revlimid in NDMM Patients
  • Table 50 Summary of Phase III Pivotal Trial Results for Revlimid in RRMM Patients
  • Table 51: Summary of Frequent Grade 3 and 4 AEs in a Phase III Trial for Revlimid
  • Table 52: Revlimid SWOT Analysis, 2015
  • Table 53: Global Sales Forecast ($m) for Revlimid, 2013-2023
  • Table 54: Product Profile - Pomalyst
  • Table 55: Summary of PFS, OS, and ORR from Phase II Trial Data for Pomalyst
  • Table 56: Summary of Phase III Trial Data for Pomalyst
  • Table 57: Pomalyst SWOT Analysis, 2015
  • Table 58: Global Sales Forecasts ($m) for Pomalyst, 2013-2023
  • Table 59: Summary of Other Therapeutic Classes, 2015
  • Table 60: Pipeline Product Profile - Farydak
  • Table 61: Summary of the Phase III PANORAMA 1 Trial of Farydak
  • Table 62: Summary of the Phase III PANORAMA 1 Trial of Farydak in Patients Who Recived at Least Two Prior Lines of Therapy (Including Velcade and an IMiD)
  • Table 63: Summary of the Phase II PANORAMA 2 Trial of Farydak
  • Table 64: Grade 3-4 Adverse Events in the Phase III PANORAMA 1 Trial of Farydak
  • Table 65: Farydak SWOT Analysis, 2015
  • Table 66: Global Sales Forecast ($m) for Farydak, 2013-2023
  • Table 67: Pipeline Product Profile - Ixazomib
  • Table 68: Response Results from the Phase II Study of Ixazomib
  • Table 69: Ixazomib SWOT Analysis, 2015
  • Table 70: Global Sales Forecast ($m) for Ixazomib, 2013-2023
  • Table 71: Pipeline Product Profile - Empliciti
  • Table 72: Summary of the Phase III ELOQUENT 2 trial of Empliciti
  • Table 73: Efficacy Results from the Phase II Study of Empliciti with Velcade and Dexamethasone
  • Table 74: Empliciti SWOT Analysis, 2015
  • Table 75: Global Sales Forecast ($m) for Empliciti, 2013-2023
  • Table 76: Pipeline Product Profile - Daratumumab
  • Table 77: Response Results from the Phase II Study of Daratumumab
  • Table 78: Daratumumab SWOT Analysis, 2015
  • Table 79: Global Sales Forecast ($m) for Ddaratumumab, 2013-2023
  • Table 80: Pipeline Product Profile - Aplidin
  • Table 81: Summary of Phase II Clinical Trial Results for Aplidin
  • Table 82: Summary of Grade 3 and 4 Adverse Events of Aplidin
  • Table 83: Aplidin SWOT Analysis, 2015
  • Table 84: Global Sales Forecast ($m) for Aplidin, 2013-2023
  • Table 85: Summary of Efficacy Data from the Phase Ib/II Clinical Trial of Oprozomib
  • Table 86: Summary of the Phase I Efficacy Results of SAR650984
  • Table 87: Summary of the Phase I Efficacy Results of Evofosfamide
  • Table 88: Key Companies in the Multiple Myeloma Market Across the 8MM, 2013-2023
  • Table 89: Millennium Pharmaceuticals Multiple Myeloma Therapy Portfolio Assessment, 2015
  • Table 90: Celgene's Multiple Myeloma Therapy Portfolio Assessment, 2015
  • Table 91: Onyx Pharmaceuticals Multiple Myeloma Therapy Portfolio Assessment, 2015
  • Table 92: Novartis' Multiple Myeloma Therapy Portfolio Assessment, 2015
  • Table 93: AbbVie's Multiple Myeloma Therapy Portfolio Assessment, 2015
  • Table 94: BMS' Multiple Myeloma Therapy Portfolio Assessment, 2015
  • Table 95: Janssen's Multiple Myeloma Therapy Portfolio Assessment, 2015
  • Table 96: Annual Global Sales ($m) for Multiple Myeloma by Region, 2013-2023
  • Table 97: Annual Global Sales ($m) for Multiple Myeloma by Drug, 2013-2023
  • Table 98: Global Multiple Multiple Myeloma - Drivers, 2013-2023
  • Table 99: Global Multiple Multiple Myeloma - Barriers, 2013-2023
  • Table 100: US Sales Forecast, Multiple Myeloma, 2013-2023 ($m)
  • Table 101: Key Events Impacting Sales for Multiple Myeloma in the US, 2013-2023
  • Table 102: US Multiple Myeloma - Drivers, 2013-2023
  • Table 103: US Multiple Myeloma - Barriers, 2013-2023
  • Table 104: 5EU Sales Forecast, Multiple Myeloma, 2013-2023 ($m)
  • Table 105: Key Events Impacting Sales for Multiple Myeloma in the 5EU, 2013-2023
  • Table 106: 5EU Multiple Myeloma - Drivers and Barriers, 2013-2023
  • Table 107: 5EU Multiple Myeloma - Barriers, 2013-2023
  • Table 108: Japan Sales Forecasts, Multiple Myeloma, 2013-2023 ($m)
  • Table 109: Key Events Impacting Sales for Multiple Myeloma in Japan, 2013-2023
  • Table 110: Japanese Multiple Myeloma - Drivers, 2013-2023
  • Table 111: Japanese Multiple Myeloma - Barriers, 2013-2023
  • Table 112: China (Urban) Sales Forecast, Multiple Myeloma, 2013-2023 ($m)
  • Table 113: Key Events Impacting Sales for Multiple Myeloma in China 2013-2023
  • Table 114: Chinese (Urban) Multiple Myeloma - Drivers, 2013-2023
  • Table 115: Chinese (Urban) Multiple Myeloma - Barriers, 2013-2023
  • Table 116: Multiple Myeloma Diagnosed Incidence, 2013-2023
  • Table 117: Multiple Myeloma Drugs and Pipeline agents, Launch Dates
  • Table 118: Multiple Myeloma Drugs and Pipeline agents, Anticipated Patent Expiries
  • Table 119: Average Cost of Therapy for Velcade
  • Table 120: Average Duration of Treatment (Weeks) for Velcade
  • Table 121: Average Cost of Therapy for Kyprolis ($)
  • Table 122: Average Duration of Treatment (Weeks) for Kyprolis
  • Table 123: Average Cost of Therapy for Revlimid ($)
  • Table 124: Average Duration of Treatment (Weeks) for Revlimid
  • Table 125: Average Cost of Therapy for Pomalyst/Imnovid ($)
  • Table 126 Average Duration of Treatment (Weeks) for Pomalyst/Imnovid
  • Table 127: Average Cost of Therapy for Farydak ($)
  • Table 128: Duration of Treatment (Weeks) for Farydak
  • Table 129: Average Cost of Therapy for Ixazomib ($)
  • Table 130: Duration of Treatment (Weeks) for Ixazomib
  • Table 131: Average Cost of Therapy for Empliciti ($)
  • Table 132: Duration of Treatment (Weeks) for Empliciti
  • Table 133: Average Cost of Therapy for Daratumumab ($)
  • Table 134: Duration of Treatment (Weeks) for Daratumumab
  • Table 135: Average Cost of Therapy for Daratumumab ($)
  • Table 136: Duration of Treatment (Weeks) for Daratumumab
  • Table 137: Numbers of Prescribers Surveyed in Each Country

List of Figures

  • Figure 1: 8MM, Diagnosed Incident Cases of Multiple Myeloma, Both Sexes, Ages ≥40 Years, N, 2013-2023
  • Figure 2: 8MM, Age-Specific Diagnosed Incident Cases of Multiple Myeloma, Both Sexes, N, 2013
  • Figure 3: 8MM, Sex-Specific Diagnosed Incident Cases of Multiple Myeloma, Ages ≥40 Years, N, 2013
  • Figure 4: 8MM, Age-Standardized Diagnosed Incidence of Multiple Myeloma (Cases per 100,000 Population), Ages ≥40 Years, by Sex, 2013
  • Figure 5: 8MM, Diagnosed Incident Cases of Multiple Myeloma by Clinical Stage at Diagnosis, Ages ≥40 Years, N, 2013
  • Figure 6: 8MM, Five-Year Diagnosed Prevalent Cases of Multiple Myeloma, Both Sexes, Ages ≥40 Years, N, 2013-2023
  • Figure 7: SCT-Eligible Typical Patient Journey
  • Figure 8: Non-SCT-Eligible Typical Patient Journey
  • Figure 9: Velcade's Phase III Development in Multiple Myeloma
  • Figure 10: Kyprolis's Phase III Development in Multiple Myeloma
  • Figure 11: Revlimid's Phase III Development in Multiple Myeloma
  • Figure 12: Pomalyst/Imnovid's Phase III Development in Multiple Myeloma
  • Figure 13: Farydak's Development in Multiple Myeloma
  • Figure 14: Dosing Schedule for Farydak
  • Figure 15: Ixazomib's Development in Multiple Myeloma
  • Figure 16: Empliciti's Development in Multiple Myeloma
  • Figure 17: Daratumumab's Development in Multiple Myeloma
  • Figure 18: Global Sales ($m) of Branded Products for Multiple Myeloma by Company, 2013 - 2023
  • Figure 19: Company Portfolio Gap Analysis in Multiple Myeloma, 2013-2023
  • Figure 20: Annual Global Sales for Multiple Myeloma by Region, 2013-2023
  • Figure 21: Annual Global Sales for Multiple Myeloma by Region - 2013, 2023
  • Figure 22: Annual Global Sales for Multiple Myeloma by Drug, 2013-2023
  • Figure 23: Global Sales for Multiple Myeloma by Drug, 2013 - 2023
  • Figure 24: Annual US Sales for Multiple Myeloma by Drug, 2013-2023
  • Figure 25: US Sales for Multiple Myeloma by Drug, 2013 and 2023
  • Figure 26: Annual 5EU Sales for Multiple Myeloma by Region, 2013-2023
  • Figure 27: Annual 5EU Sales for Multiple Myeloma by Drug, 2013-2023
  • Figure 28: 5EU Sales for Multiple Myeloma by Drug, 2013 and 2023
  • Figure 29: Annual Japanese Sales for Multiple Myeloma by Drug, 2013-2023
  • Figure 30: Japanese Sales for Multiple Myeloma by Drug, 2013 and 2023
  • Figure 31: Annual Chinese (Urban) Sales for Multiple Myeloma by Drug, 2013-2023
  • Figure 32: Chinese (Urban) Sales for Multiple Myeloma by Drug, 2013 and 2023
Back to Top